Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) has moved into the second stage of its previously-announced program to determine the three-dimensional structure of NR2F6 – with and without its proprietary small molecule drugs bound to it. The object of this structure-determination program is to shed light on how the small molecules bind to and modulate NR2F6 activity.